Complete financial analysis of Cognetivity Neurosciences Ltd. (CGNSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cognetivity Neurosciences Ltd., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Unipar Carbocloro S.A. (UNIP3.SA) Income Statement Analysis – Financial Results
- Brighthouse Financial, Inc. (BHF) Income Statement Analysis – Financial Results
- Servyou Software Group Co., Ltd. (603171.SS) Income Statement Analysis – Financial Results
- AudioCodes Ltd. (AUDC) Income Statement Analysis – Financial Results
- Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) Income Statement Analysis – Financial Results
Cognetivity Neurosciences Ltd. (CGNSF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.cognetivity.com
About Cognetivity Neurosciences Ltd.
Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that helps to detect the earliest signs of impairment by testing the performance of large areas of the brain to support the diagnosis of dementia; and offers OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.18M | 24.53K | 11.45K | 9.29K | 3.94K | 1.43K | 240.00 | 10.97K |
| Gross Profit | -2.13M | -24.53K | -11.45K | -9.29K | -3.94K | -1.43K | -240.00 | -10.97K |
| Gross Profit Ratio | -4,694.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 601.15K | 491.23K | 71.00K | 492.18K | 732.37K | 82.14K | 63.09K | 0.00 |
| General & Administrative | 5.04M | 11.52M | 2.09M | 1.61M | 2.46M | 1.34M | 368.65K | 51.49K |
| Selling & Marketing | 575.70K | 945.81K | 230.80K | 402.02K | 855.93K | 8.37K | 27.78K | 17.47K |
| SG&A | 5.61M | 12.47M | 2.32M | 2.01M | 3.32M | 1.35M | 396.42K | 71.15K |
| Other Expenses | -6.17M | 21.00K | 580.10K | 778.00 | -432.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 45.37K | 13.06M | 2.46M | 2.61M | 4.21M | 1.49M | 476.80K | 57.68K |
| Cost & Expenses | 6.34M | 13.06M | 2.46M | 2.61M | 4.21M | 1.49M | 476.80K | 68.65K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 21.40K | 5.24K | 150.00 | 0.00 |
| Interest Expense | 1.03M | 60.55K | 62.84K | 55.98K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 24.63K | 24.53K | 11.45K | 9.29K | 3.94K | 1.43K | 240.00 | 82.12K |
| EBITDA | -6.38M | -13.01M | -1.87M | -2.60M | -4.21M | -1.49M | -494.36K | -0.34 |
| EBITDA Ratio | -14,067.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.29M | -13.04M | -1.88M | -2.60M | -4.21M | -1.49M | -494.60K | -82.12K |
| Operating Income Ratio | -13,866.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.14M | -148.04K | 467.46K | -126.11K | -105.77K | -8.94K | 17.72K | 13.47K |
| Income Before Tax | -7.43M | -13.13M | -1.93M | -2.66M | -4.19M | -1.50M | -458.84K | -68.65K |
| Income Before Tax Ratio | -16,386.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 81.56K | 2.29K | -15.18K | -21.83K | 1.85K | -17.96K | 13.47K |
| Net Income | -7.43M | -13.13M | -1.93M | -2.65M | -4.19M | -1.50M | -458.84K | -68.65K |
| Net Income Ratio | -16,386.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.09 | -0.18 | -0.03 | -0.06 | -0.10 | -0.04 | -0.01 | 0.00 |
| EPS Diluted | -0.09 | -0.18 | -0.03 | -0.06 | -0.10 | -0.04 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 85.05M | 73.06M | 58.68M | 45.60M | 40.41M | 41.45M | 41.45M | 30.01M |
| Weighted Avg Shares Out (Dil) | 85.05M | 73.06M | 58.68M | 45.60M | 40.41M | 41.45M | 41.45M | 30.00M |
CognICA(TM) Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service
Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Savings of Over £40 Million Per Year Compared with Traditional Cognitive Assessment Tools in Primary and Secondary Care...
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA
Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's Drugs Vancouver, British Columbia--(Newsfile Corp. - October 11, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF)...
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated Care Vancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a...
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North America Vancouver, British Columbia--(Newsfile Corp. - September 21, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or...
Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award
CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence...
Cognetivity Neurosciences' AI Powered CognICA Platform Shortlisted for Major Industry Award
CognICA Shortlisted for Most Innovative AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI)...
Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease
Cognetivity's Landmark ADePT Study, Funded by the UK Innovation Agency and Published in Leading Neuroscience Journal Demonstrates Unprecedented Sensitivity in Detecting Cognitive Impairment in Early Stage Alzheimer's Disease, Essential for Treatment With New Drugs Vancouver, British Columbia--(Newsfile Corp. - August...
Cognetivity Neurosciences Announces Successful Registration With Health Canada for Clinical use of CognICA(TM) AI-Powered Brain Health Technology in Canada
Approval opens up a new major market for CognICA, providing a solution to the urgent requirement for large-scale early detection and monitoring for the rollout of incoming Alzheimer's disease drugs Vancouver, British Columbia--(Newsfile Corp. - August 2, 2023) - Cognetivity...
New Disease Modifying Drug for Alzheimer's Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring
Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal role in early detection and monitoring globally Vancouver, British Columbia--(Newsfile Corp. - July 7, 2023) - Cognetivity Neurosciences Ltd. (CSE:...
Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform
The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or...
Source: https://incomestatements.info
Category: Stock Reports